Hoshi Iryo-Sanki (7634) Fundamentals 2026 — P/E 11.8x, Revenue Analysis | SniperIQ
Hoshi Iryo-Sanki (7634) is a JP-listed Healthcare company in Medical - Equipment & Services with a market capitalization of ¥16.2B, trading at ¥5200.00 on the JPX. This SniperIQ fundamentals page covers Hoshi Iryo-Sanki's valuation (P/E 11.8x, P/B 0.8x), profitability (net margin 8.8%), revenue (¥15.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hoshi Iryo-Sanki's market cap?
Hoshi Iryo-Sanki (7634) has a market capitalization of approximately ¥16.2B, trading at ¥5200.00 on the JPX. Market cap moves with the live share price.
What is Hoshi Iryo-Sanki's P/E ratio?
Hoshi Iryo-Sanki's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hoshi Iryo-Sanki?
Hoshi Iryo-Sanki runs a net profit margin of 8.8%, a gross margin of 49.5%, and an operating margin of 12.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hoshi Iryo-Sanki generate?
Hoshi Iryo-Sanki reported revenue of ¥15.5B for fiscal year 2025, with net income of ¥1.4B and earnings per share (EPS) of 439.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hoshi Iryo-Sanki pay a dividend?
Hoshi Iryo-Sanki offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hoshi Iryo-Sanki financially healthy?
Hoshi Iryo-Sanki carries a debt-to-equity ratio of 0.06x and a current ratio of 3.17x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hoshi Iryo-Sanki a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hoshi Iryo-Sanki (7634) the key facts are: market cap ¥16.2B, P/E 11.8x, revenue ¥15.5B, 52-week range 4500-6000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hoshi Iryo-Sanki's full fundamentals live
Get Hoshi Iryo-Sanki's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.